Home
About Us
News
R&D
Manufacture
Products
Culture
Qingfeng Pharmaceutical Group
中文
English
News
Qingfeng will attend the 2025 J.P. Morgan Healthcare Conference
Qingfeng Pharmaceutical's Eribulin Mesilate Injection Approved for Marketing in the U.S.
First in China! Qingfeng Pharmaceutical's Brivaracetam Tablets Approved for Marketing
The application for the NDA of the new anti-influenza drug GP681 tablets was accepted by NMPA
Great news! Qingfeng Pharmaceutical's Enzalutamide API and Soft Capsules are approved for marketing in the United States